GlassScriptPhysician profile
Anjuli K Suda
NPI 1467404434
$4,311.13
in general payments reported to CMS, 2019-2025
38 companies · $46.07 in 2025
The $46.07 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $1,013 · 2021: $687 · 2022: $505 · 2023: $881 · 2024: $272 · 2025: $46.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $508.60 | 2019-2024 | Ozempic |
| Abbott Laboratories | $410.39 | 2020-2024 | Freestyle Libre 3 |
| Pfizer INC. | $393.60 | 2019-2024 | |
| Mannkind Corporation | $327.28 | 2019-2024 | Afrezza |
| Amgen INC. | $258.25 | 2019-2024 | Repatha |
| Cranial Technologies, INC | $233.88 | 2019-2024 | Doc Band |
| Senseonics, Incorporated | $221.00 | 2019-2020 | |
| Sanofi Pasteur INC. | $183.99 | 2019-2025 | |
| Kaleo, INC. | $171.08 | 2019-2023 | Auvi-Q |
| Boston Scientific Corporation | $150.00 | 2023 | Watchman Flx |
| Merck Sharp & Dohme LLC | $126.53 | 2019-2021 | |
| Glaxosmithkline, LLC. | $125.64 | 2020-2023 | Bexsero, Pediarix, Rotarix |
| Lilly USA, LLC | $108.36 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $97.65 | 2019-2021 | |
| Medtronic Minimed, INC. | $94.41 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjuli Suda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.